Practical recommendations for the treatment of ascites and its complications

被引:12
作者
Bataller, R [1 ]
Gines, P [1 ]
Arroyo, V [1 ]
机构
[1] UNIV BARCELONA,HOSP CLIN & PROV,LIVER UNIT,E-08036 BARCELONA,SPAIN
关键词
D O I
10.2165/00003495-199754040-00004
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Ascites is one of the earliest and most common complications of patients with cirrhosis, and is associated with complications such as dilutional hyponatraemia, renal dysfunction and spontaneous bacterial peritonitis. The treatment of ascites has been based on the combination of a low-sodium diet and the administration of diuretics. The reintroduction of paracentesis and the recent introduction of the transjugular intrahepatic portosystemic shunt (TIPS) are the most relevant innovations in the treatment of ascites during the past 2 decades. The development of ascites is closely related to renal disturbances of functional origin, including the hepatorenal syndrome. A new definition of hepatorenal syndrome has been proposed recently and 2 different types have been defined (type I or progressive, and type II or stable). Although no effective therapy exists for this syndrome, the use of therapeutic methods (TIPS, vasoconstrictor agents, dialysis) to temporarily improve renal function and act as a 'bridge' to liver transplantation, may be of most benefit. The use of potent and safe antibiotics has improved the resolution rate and survival of patients with spontaneous bacterial peritonitis. In addition, the use of oral antibiotics will simplify the management of this condition in the near future. Finally, prophylactic antibiotic regimens represent a major step forwards in the prevention of spontaneous bacterial peritonitis in subsets of cirrhotic patients with a great risk of developing this complication.
引用
收藏
页码:571 / 580
页数:10
相关论文
共 55 条
[1]   RISK-FACTORS FOR SPONTANEOUS BACTERIAL PERITONITIS IN CIRRHOTIC-PATIENTS WITH ASCITES [J].
ANDREU, M ;
SOLA, R ;
SITGESSERRA, A ;
ALIA, C ;
GALLEN, M ;
VILA, MC ;
COLL, S ;
OLIVER, MI .
GASTROENTEROLOGY, 1993, 104 (04) :1133-1138
[2]  
ANGELI P, 1994, HEPATOLOGY, V19, P72, DOI 10.1002/hep.1840190113
[3]   Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis [J].
Arroyo, V ;
Gines, P ;
Gerbes, AL ;
Dudley, FJ ;
Gentilini, P ;
Laffi, G ;
Reynolds, TB ;
RingLarsen, H ;
Scholmerich, J .
HEPATOLOGY, 1996, 23 (01) :164-176
[4]   PROGNOSTIC VALUE OF SPONTANEOUS HYPONATREMIA IN CIRRHOSIS WITH ASCITES [J].
ARROYO, V ;
RODES, J ;
GUTIERREZLIZARRAGA, MA ;
REVERT, L .
AMERICAN JOURNAL OF DIGESTIVE DISEASES, 1976, 21 (03) :249-256
[5]  
ARROYO V, 1994, INFECTION S3, V22, pS1
[6]  
Bernard B., 1996, Hepatology, V24, p444A
[7]   AQUARETIC EFFECT OF THE KAPPA-OPIOID AGONIST RU-51599 IN CIRRHOTIC RATS WITH ASCITES AND WATER-RETENTION [J].
BOSCHMARCE, M ;
JIMENEZ, W ;
ANGELI, P ;
LEIVAS, A ;
CLARIA, J ;
GRAZIOTTO, A ;
ARROYO, V ;
RIVERA, F ;
RODES, J .
GASTROENTEROLOGY, 1995, 109 (01) :217-223
[8]  
CABRERA J, 1982, GASTROENTEROLOGY, V82, P97
[9]  
DADANO A, 1996, HEPATOLOGY, V24, pA448
[10]   RAPID EMERGENCE OF QUINOLONE RESISTANCE IN CIRRHOTIC-PATIENTS TREATED WITH NORFLOXACIN TO PREVENT SPONTANEOUS BACTERIAL PERITONITIS [J].
DUPEYRON, C ;
MANGENEY, N ;
SEDRATI, L ;
CAMPILLO, B ;
FOUET, P ;
LELUAN, G .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1994, 38 (02) :340-344